|
|
||||||||
Ann Thorac Surg 2006;81:104-111
© 2006 The Society of Thoracic Surgeons
a Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland
b Department of Radiology, University of Maryland School of Medicine, Baltimore, Maryland
c Department of Clinical Effectiveness, University of Maryland School of Medicine, Baltimore, Maryland
d Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland
e Chronolog Corp, Havertown, Pennsylvania
f Sinai Center for Thrombosis Research, Baltimore, Maryland
Accepted for publication May 10, 2005.
* Address correspondence to Dr Poston, Division of Cardiac Surgery, N4W94 22 S Greene St, Baltimore, MD 21201 (Email: rposton{at}smail.umaryland.edu).
Presented at the Forty-first Annual Meeting of The Society of Thoracic Surgeons, Tampa, FL, Jan 2426, 2005.
BACKGROUND: Hemostatic drugs are widely thought to be unnecessary and potentially detrimental in off-pump coronary artery bypass graft surgery (OPCABG), despite well-established use in on-pump surgery. In a randomized, prospective OPCABG trial, we assessed efficacy and safety of aprotinin through a comprehensive assessment of graft patency and hematologic function.
METHODS: Sixty patients were randomly assigned to full-dose aprotinin or placebo. Heparin was titrated to a kaolin-based activated clotting time of greater than 300 seconds. Exclusionary criteria included creatinine greater than 2 mg/dL, conversion to on-pump CABG, and preoperative GPIIb/IIIa inhibition. Hematologic assessments were obtained preoperatively, at the end of surgery, and on days 1 and 3: mean platelet volume, thrombin generation (prothrombin fragment 1.2 assay), and aspirin resistance using a modified thrombelastography, whole blood aggregometry, 11-dehydro-thromboxane B2 levels, and flow cytometry. Thrombotic events were defined as postoperative myocardial infarction by electrocardiography or elevated troponin I, clinical stroke by examination and head computed tomography, and bypass graft failure by multichannel computed tomography angiography on day 5.
RESULTS: Aprotinin was associated with a significant reduction in intraoperative and postoperative blood loss compared with placebo but had no effect on transfusion rates. Patients treated with aprotinin had significantly fewer thrombotic events (3% versus 23%, p < 0.05, Fisher's exact test) and less postoperative aspirin resistance (20% versus 46%, respectively, p < 0.05, Fisher's exact test). Postoperative prothrombin fragment 1.2 level was reduced by aprotinin use.
CONCLUSIONS: Aprotinin reduced perioperative bleeding after OPCABG. Preserved aspirin sensitivity in the aprotinin group may explain the observed reduction in thrombotic events and might be related to the suppression of perioperative and transmyocardial thrombin formation.
This article has been cited by other articles:
![]() |
P. H. Desai, D. Kurian, N. Thirumavalavan, S. P. Desai, P. Ziu, M. Grant, C. White, R. C. Landis, and R. S. Poston A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulabilityin Off-Pump Coronary Surgery Anesth. Analg., November 1, 2009; 109(5): 1387 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, Z. Zheng, H. Ao, S. Zhang, Y. Wang, H. Zhang, L. Li, and S. Hu A comparison before and after aprotinin was suspended in cardiac surgery: Different results in the real world from a single cardiac center in China J. Thorac. Cardiovasc. Surg., October 1, 2009; 138(4): 897 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dai, A. Lee, L. A. H. Critchley, and P. F. White Does Thromboelastography Predict Postoperative Thromboembolic Events? A Systematic Review of the Literature Anesth. Analg., March 1, 2009; 108(3): 734 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Nurozler, T. Kutlu, and G. Kucuk Aprotinin for Patients Exposed to Clopidogrel Before Off-Pump Coronary Bypass Asian Cardiovasc Thorac Ann, December 1, 2008; 16(6): 483 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Bittner, J. Lemke, M. Lange, A. Rastan, and F. W. Mohr The Impact of Aprotinin on Blood Loss and Blood Transfusion in Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 2008; 85(5): 1662 - 1668. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. N. Kon, E. N. Brown, M. C. Grant, T. Ozeki, N. S. Burris, M. J. Collins, M. H. Kwon, and R. S. Poston Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 215 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rukosujew, S. Klotz, C. Reitz, W. Gogarten, H. Welp, and H. H. Scheld Patients and complication with off-pump vs. on-pump cardiac surgery a single surgeon experience Interactive CardioVascular and Thoracic Surgery, December 1, 2007; 6(6): 768 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Brown, Z. N. Kon, R. Tran, N. S. Burris, J. Gu, P. Laird, P. S. Brazio, S. Kallam, K. Schwartz, L. Bechtel, et al. Strategies to reduce intraluminal clot formation in endoscopically harvested saphenous veins. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1259 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Levy and S. Force Invited commentary Ann. Thorac. Surg., September 1, 2007; 84(3): 986 - 987. [Full Text] [PDF] |
||||
![]() |
R. Poston Letter by Poston Regarding Article, "Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?" Circulation, November 14, 2006; 114(20): e589 - e589. [Full Text] [PDF] |
||||
![]() |
E. I. Kapetanakis, D. A. Medlam, K. R. Petro, P. C. Hill, M. K. C. Dullum, A. S. Bafi, S. W. Boyce, P. J. Corso, and E. Haile Response to Letters Regarding Article, "Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery: Are We Forfeiting the Benefits of Reduced Hemorrhagic Sequelae?" Circulation, November 14, 2006; 114(20): e590 - e590. [Full Text] [PDF] |
||||
![]() |
R. Poston and O. Toshinaga Reply Ann. Thorac. Surg., November 1, 2006; 82(5): 1951 - 1952. [Full Text] [PDF] |
||||
![]() |
T. Vanek, M. Jares, Z. Straka, and MSM0021620817 Study Group Aprotinin Reduces Troponin I Levels in OPCABG Ann. Thorac. Surg., November 1, 2006; 82(5): 1950 - 1951. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |